Incidence and predictive factors for recurrent clear cell ovarian carcinoma: results from a single center in Thailand

Abstract

We aimed to study the incidence and predictive factors of recurrent clear cell ovarian carcinoma (CCC) and evaluate the oncological outcomes after recurrence. MethodsThis was a retrospective study of 134 CCC cases diagnosed between 2005 and 2020.Clinicopathological data and oncological outcomes were extracted and evaluated. Patients with comalignancy, mixed pathological type, or incomplete data were excluded. Descriptive statistics, univariate and multivariable analyses, and Kaplan-Meier survival probability estimates were completed. A proportional hazards model was used to assess the association between the prognostic factors with progression-free survival (PFS), overall survival (OS), and post-recurrence survival. ResultsA total of 134 patients with CCC were enrolled. The incidence of recurrent CCC was 33.6% (45/134).The median PFS was 12.8 months (95% confidence interval [CI], 9.66-18.9) in the recurrence group and 3.3 months (95% CI, 1.15-4.4) in the refractory group. Residual tumor from surgical outcome, ascites cytology, and lymphovascular space invasion (LVSI) were independent prognostic factors for PFS. The significant variables were residual tumor (sub-optimal surgery vs. optimal surgery) (hazard

Repurposing Drugs in Controlling Recurrent Platinum-Resistant Clear-Cell Ovarian Cancer

“…This type of cancer often affects younger patients. Hemman and Rattanaburi conducted a study in the Thai population and found that patients with recurrent PRCCC who received an additional line of chemotherapy had an estimated survival time of 7.8 months [ 17 ]. The results of our patient align with these findings, as she had a progression-free survival of 2 months and an overall survival of 8.5 months.…”